News
TipRanks on MSN20h
AstraZeneca’s Phase III Breast Cancer Study: A Potential Game Changer?
AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase III clinical study titled A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of ...
With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback